Respiratory depression

Updated: August 29, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

doxapram

0.5 - 1

mg/kg

Intravenous (IV)

repeat every 5 minutes (max. 2 mg/kg)

naloxone

Indicated for Treatment of Therapeutic Opioid Doses for Respiratory Depression
:

Administer 0.04-0.4 mg Intravenously, Intramuscularly, or Subcutaneously first; repeat as necessary to get the desired response; if the desired response is not seen after 0.8 mg total, explore other reasons for respiratory depression.

Opioid Postoperative Depression
Administer 0.1 to 0.2 mg intravenously every 2-3 minutes until the appropriate degree of reversal (i.e., adequate breathing and awareness without considerable discomfort).
Depending on the quantity, type (e.g., short-acting or long-acting), and duration of the last dosage delivered, it may be repeated within 1 to 2 hours; supplementary intramuscular doses have resulted in long-term effects.

nikethamide

It is indicated in the treatment for respiratory depression
The recommended dose is 1-2 ml per one time a day via IV or SC

Dose Adjustments

Limited data is available

doxapram

>12 years and adolescents:

0.5 - 1

mg/kg

Intravenous (IV)

repeat every 5 minutes (max. 2 mg/kg)

Future Trends